Literature DB >> 2925240

Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.

A F Verheul1, A A Versteeg, M J De Reuver, M Jansze, H Snippe.   

Abstract

Streptococcus pneumoniae type 14 capsular polysaccharide-bovine serum albumin (S14PS-BSA) conjugates were prepared by water-soluble-carbodiimide-mediated condensation with or without the use of N-hydroxy-sulfosuccinimide. The immunogenicities of the capsular polysaccharide (S14PS) and of the conjugates were studied in (CBA/N x BALB/c)F1 mice and in female BALB/c mice. The response in these mice indicates that S14PS could be classified as a thymus-independent type 2 antigen. Coupling of S14PS to BSA improved the immunogenicity of this polysaccharide, and an immunoglobulin G memory response was evoked. Conjugation with N-hydroxysulfosuccinimide resulted in a product with a higher polysaccharide/protein ratio. This conjugate induced a greater immune response than did the classical conjugate. Quil A enhanced the immune response to S14PS and to most S14PS-BSA conjugates. The enhancement of the immune response to the conjugates seemed to depend on the coupling procedure. Our results indicate that for the construction of immunostimulating complexes based on polysaccharide or oligosaccharide-protein conjugates, attention should be paid to the degree of cross-linking of the antigens involved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925240      PMCID: PMC313232          DOI: 10.1128/iai.57.4.1078-1083.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Enzyme-linked immunosorbent assay determination of specific rubella antibody levels in micrograms of immunoglobulin G per milliliter of serum in clinical samples.

Authors:  P O Leinikki; I Shekarchi; P Dorsett; J L Sever
Journal:  J Clin Microbiol       Date:  1978-10       Impact factor: 5.948

3.  Quantitative studies of the specificity of anti-pneumococcal polysaccharide antibodies, types 3 and 8. I. Isolation of oligosaccharides from acid and from enzymatic hydrolysates of S3 and S8.

Authors:  J H Campbell; A M Pappenheimer
Journal:  Immunochemistry       Date:  1966-05

4.  Artificial Salmonella vaccines.

Authors:  S B Svenson; A A Lindberg
Journal:  Prog Allergy       Date:  1983

Review 5.  Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids.

Authors:  J D Aplin; J C Wriston
Journal:  CRC Crit Rev Biochem       Date:  1981

Review 6.  Bacterial capsular polysaccharides--biochemistry, immunity and vaccine.

Authors:  C J Lee
Journal:  Mol Immunol       Date:  1987-10       Impact factor: 4.407

7.  Characterization by gas-liquid chromatography-mass spectrometry and proton-magnetic-resonance spectroscopy of pertrimethylsilyl methyl glycosides obtained in the methanolysis of glycoproteins and glycopeptides.

Authors:  J P Kamerling; G J Gerwig; J F Vliegenthart; J R Clamp
Journal:  Biochem J       Date:  1975-12       Impact factor: 3.857

8.  Immune response of neonates to pneumococcal polysaccharide-protein conjugate.

Authors:  K T Lin; C J Lee
Journal:  Immunology       Date:  1982-06       Impact factor: 7.397

Review 9.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  19 in total

1.  Cholera toxin B-subunit gene fusion: structural and functional analysis of the chimeric protein.

Authors:  M T Dertzbaugh; D L Peterson; F L Macrina
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

5.  Monitoring of the response of elderly individuals to pneumococcal vaccination with the aid of a novel ELISA.

Authors:  M Fattal-German; B Bizzini
Journal:  Eur J Epidemiol       Date:  1990-12       Impact factor: 8.082

6.  Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Authors:  Dodi Safari; Huberta A T Dekker; John A F Joosten; Dirk Michalik; Adriana Carvalho de Souza; Roberto Adamo; Martina Lahmann; Andreas Sundgren; Stefan Oscarson; Johannis P Kamerling; Harm Snippe
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

7.  Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.

Authors:  E Alonso de Velasco; A F Verheul; A M van Steijn; H A Dekker; R G Feldman; I M Fernández; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

Review 8.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

9.  Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

Authors:  A F Verheul; A K Braat; J M Leenhouts; P Hoogerhout; J T Poolman; H Snippe; J Verhoef
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

Review 10.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.